{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05584670",
            "orgStudyIdInfo": {
                "id": "TCD17620"
            },
            "secondaryIdInfos": [
                {
                    "id": "U1111-1277-4827",
                    "type": "REGISTRY",
                    "domain": "ICTRP"
                },
                {
                    "id": "2022-001239-95",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Sanofi",
                "class": "INDUSTRY"
            },
            "briefTitle": "A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors",
            "officialTitle": "A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-first-in-human-dose-escalation-and-dose-expansion-study-of-in-adult-participants-with-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-01-19",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-09-27",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-10-07",
            "studyFirstSubmitQcDate": "2022-10-13",
            "studyFirstPostDateStruct": {
                "date": "2022-10-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sanofi",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors.\n\nThe study will include 2 parts:\n\nA dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable.\n\nA multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab: 2 recommended doses for expansion/optimization of SAR445877 identified from dose escalation part 1 will be tested in different indications in monotherapy and in combination with other anticancer therapies as applicable.\n\nApproximately 285 participants will be enrolled to the study intervention: approximately 75 participants in part 1 and up to 210 participants in expansion/dose optimization part (part 2).",
            "detailedDescription": "The duration of the study for a participant will include:\n\nScreening Period: up to 28 days Treatment Period: enrolled and exposed participants will receive continuous treatment until progressive disease (PD), or an occurrence of an unacceptable AE, a withdrawal of consent, or until other permanent discontinuation criteria described in the protocol are met.\n\nThe End of Treatment (EOT) visit will occur 30 days \u00b17 days from the last IMP administration or prior to the initiation of further therapy, whichever occurs first.\n\nThe follow-up period will occur until disease progression, the start of new anticancer therapy, death, or withdrawal of participant's consent, whichever comes first."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 285,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "SAR445877 Escalation Phase (Part 1)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered intravenously in patients with solid tumors over a 14-day cycle.",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort A1 (Part 2A)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered intravenously (IV) in patients with non-small cell lung cancer (NSCLC).",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort A2 (Part 2A)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered intravenously in patients with non-small cell lung cancer (NSCLC).",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort B (Part 2A)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered IV in patients with hepatocellular carcinoma (HCC).",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort C1 (Part 2A)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered IV in patients with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort C2 (Part 2A)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered IV in patients with gastric cancer/gastro esophageal junction adenocarcinoma (GC/GEJ).",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort D (Part 2A)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered IV in patients with immune infiltrated tumor type.",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort E1 (Part 2A)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered IV in patients with colorectal cancer (CRC).",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort E2 (Part 2A)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 monotherapy will be administered IV in patients with colorectal cancer (CRC).",
                    "interventionNames": [
                        "Drug: SAR445877"
                    ]
                },
                {
                    "label": "SAR445877 Expansion/Optimization Phase: Cohort E3 (Part 2B)",
                    "type": "EXPERIMENTAL",
                    "description": "SAR445877 will be administered IV in combination with cetuximab in patients with colorectal cancer (CRC).",
                    "interventionNames": [
                        "Drug: SAR445877",
                        "Drug: Cetuximab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "SAR445877",
                    "description": "Concentrate for solution for infusion",
                    "armGroupLabels": [
                        "SAR445877 Escalation Phase (Part 1)",
                        "SAR445877 Expansion/Optimization Phase: Cohort A1 (Part 2A)",
                        "SAR445877 Expansion/Optimization Phase: Cohort A2 (Part 2A)",
                        "SAR445877 Expansion/Optimization Phase: Cohort B (Part 2A)",
                        "SAR445877 Expansion/Optimization Phase: Cohort C1 (Part 2A)",
                        "SAR445877 Expansion/Optimization Phase: Cohort C2 (Part 2A)",
                        "SAR445877 Expansion/Optimization Phase: Cohort D (Part 2A)",
                        "SAR445877 Expansion/Optimization Phase: Cohort E1 (Part 2A)",
                        "SAR445877 Expansion/Optimization Phase: Cohort E2 (Part 2A)",
                        "SAR445877 Expansion/Optimization Phase: Cohort E3 (Part 2B)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cetuximab",
                    "description": "Solution for infusion",
                    "armGroupLabels": [
                        "SAR445877 Expansion/Optimization Phase: Cohort E3 (Part 2B)"
                    ],
                    "otherNames": [
                        "Erbitux"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose escalation: Presence of dose-limiting toxicities (DLTs) in Cycles 1 and 2",
                    "description": "DLTs will be defined using NCI CTCAE version 5.0 or ASTCT criteria for CRS or immune effector cell-associated neurotoxicity syndrome (ICANS)",
                    "timeFrame": "Cycles 1 & 2 - 14 days per cycle"
                },
                {
                    "measure": "Dose escalation: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)",
                    "description": "Presence of TEAEs, SAEs, and lab abnormalities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading",
                    "timeFrame": "The time from the first dose of study interventions up to 30 days after last dose of study interventions"
                },
                {
                    "measure": "Dose expansion/optimization: Objective response rate (ORR)",
                    "description": "Proportion of participants who have a confirmed complete response (CR) or a partial response (PR), as the best overall response (BOR) determined by the Investigator as per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                    "timeFrame": "From baseline to the end of dose expansion/optimization (up to 2 years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Dose escalation: Objective response rate (ORR)",
                    "description": "Proportion of participants who have a confirmed complete response (CR) or a partial response (PR), as the best overall response (BOR) determined by the Investigator as per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                    "timeFrame": "From baseline to the end of dose escalation (up to 2 years)"
                },
                {
                    "measure": "Dose escalation & expansion/optimization: Duration of response (DoR)",
                    "description": "DoR is defined as the time from first documented evidence of confirmed CR or PR until progressive disease (PD) determined by Investigator per RECIST 1.1 or death from any cause, whichever occurs first",
                    "timeFrame": "From baseline to the end of study (up to 2 years)"
                },
                {
                    "measure": "Dose escalation & expansion/optimization: Assessment of SAR445877 Cmax",
                    "description": "Maximum plasma concentration observed",
                    "timeFrame": "Cycle 1 Day 1 to Day 8 or Day 14 (cycle duration of 14 days)"
                },
                {
                    "measure": "Dose escalation & expansion/optimization: Assessment of SAR445877 AUC0-T",
                    "description": "Area under the concentration versus time curve calculated using the trapezoidal method during a dosing interval (T)",
                    "timeFrame": "Cycle 1 Day 1 to Day 8 or Day 14 (cycle duration of 14 days)"
                },
                {
                    "measure": "Dose escalation & expansion/optimization: Assessment of SAR445877 Tmax",
                    "description": "First time to reach Cmax",
                    "timeFrame": "Cycle 1 Day 1 to Day 8 or Day 14 (cycle duration of 14 days)"
                },
                {
                    "measure": "Dose escalation & expansion/optimization: Assessment of Cetuximab serum concentration",
                    "description": "Pre-dose concentration",
                    "timeFrame": "Day 1 of each cycle to cycle 4 (cycle duration of 14 days)"
                },
                {
                    "measure": "Dose escalation & expansion/optimization: Incidence of anti-drug antibodies (ADAs) to SAR445877",
                    "description": "Proportion of participants with anti-drug antibodies (ADAs) to SAR445877",
                    "timeFrame": "From the first dose of Cycle 1 to 30 days after last dose of study interventions (cycle duration of 14 days)"
                },
                {
                    "measure": "Dose expansion/optimization: Time to response",
                    "description": "Time to response is defined as the time from the first administration of investigational medicinal product (IMP) to the first documented evidence of confirmed PR or CR determined by Investigator per RECIST 1.1",
                    "timeFrame": "From baseline to end of dose expansion/optimization (up to 2 years)"
                },
                {
                    "measure": "Dose expansion/optimization: Clinical Benefit Rate",
                    "description": "Clinical Benefit Rate including confirmed CR or PR at any time or stable disease (SD) of at least 6 months determined by Investigator per RECIST 1.1",
                    "timeFrame": "From baseline to end of dose expansion/optimization (up to 2 years)"
                },
                {
                    "measure": "Dose expansion/optimization: Progression-free survival",
                    "description": "PFS is defined as the time from the date of first administration of IMP to the date of the first documented disease progression determined by Investigator as per RECIST 1.1 or death from any cause, whichever occurs first",
                    "timeFrame": "From baseline to end of dose expansion/optimization (up to 2 years)"
                },
                {
                    "measure": "Dose expansion/optimization: Number of participants with Adverse events (AE)",
                    "description": "Presence of adverse events (AEs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading",
                    "timeFrame": "The time from the first dose of study interventions up to 30 days after last dose of study interventions."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Dose escalation Part 1\n\n   * Participants with advanced unresectable or metastatic solid tumors for which, in the judgement of the investigator, no standard alternative therapy is available or is not in the best interest of the participant\n2. Dose expansion/optimization Part 2\n\nCancer diagnosis:\n\n* Participants in Cohorts A1 and A2: Histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)\n* Participants in Cohort B: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic hepatocellular carcinoma (HCC), or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients (patients without cirrhosis must have had histological confirmation of diagnosis).\n* Participants in Cohorts C1 and C2: Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic gastric cancer (GC) or Siewert Type 2 \\& 3 gastro esophageal junction (GEJ) adenocarcinoma.\n* For participants in Cohorts C1 and C2: Disease with CPS scoring of \\<1 as determined at local laboratory with an Agency approved test (for the other cohorts: Disease with any CPS scoring. No need for CPS determination at local laboratory).\n* For participants in Cohorts C1 and C2: Participants must have MSI (metastatic microsatellite instability) or MMR (mismatch repair) status known or determined locally and must have non-MSI-H or proficient MMR (pMMR) disease to be eligible.\n* For participants in Cohorts C1 and C2: Participants with unknown HER2/neu status must have their HER2/neu status determined locally. Participants with HER2/neu negative are eligible. Participants with HER2/neu positive tumors must have documentation of disease progression on treatment containing an approved HER2 targeted therapy to be eligible.\n\nMeasurable Disease:\n\n* At least 1 measurable lesion per RECIST 1.1 criteria\n\nParticipants in Cohorts E1, E2 and E3\n\n* Histologically or cytologically confirmed diagnosis of advanced unresectable or metastatic colorectal cancer\n* Participants must have MSI status known or determined locally and must have non-MSI-H disease to be eligible.\n* Participants with RAS-mutant and BRAF-mutant colorectal cancer are eligible for enrollment.\n\nCapable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of \u22652.\n* Predicted life expectancy \u22643 months.\n* For participants with HCC- Cohort B (Part 2): Child Pugh Class B or C liver score. Participants with Child Pugh Class B-7 score are allowed for Part 1.\n* Diagnosed of any other malignancies, either progressing or requiring active treatments, within 2 years prior to enrollment.\n* Known active brain metastases or leptomeningeal metastases.\n* History of treatment-related immune-mediated (or immune-related) AEs from immune-modulatory agents (including but not limited to anti-PD1/PD-L1 agents and anti-cytotoxic T lymphocyte associated protein 4 monoclonal antibodies) that caused permanent discontinuation of the agent, or that were Grade 4 in severity or have not resolved to Grade \u22641.\n* Has any condition requiring ongoing/continuous corticosteroid therapy (\\>10 mg prednisone/day or an anti-inflammatory equivalent) within 1 week prior to the first dose of the study medicine.\n* Any clinically significant cardiac (including valvular) or vascular (thromboembolic disorders) disease, within 6 months prior to the first IMP administration.\n* Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-related adverse events.\n* Has a known history or any evidence of interstitial lung disease or active, non-infectious pneumonitis within 3 years prior to the first dose of the study drug.\n* Organ transplant requiring immunosuppressive treatment.\n* Uncontrolled or active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection, or has a diagnosis of immunodeficiency.\n\nNOTE: Other Inclusion/Exclusion criteria may apply.\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Trial Transparency email recommended (Toll free for US & Canada)",
                    "role": "CONTACT",
                    "phone": "800-633-1610",
                    "phoneExt": "option 6",
                    "email": "contact-us@sanofi.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Sciences & Operations",
                    "affiliation": "Sanofi",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Kansas Cancer Center Clinical Research Center (Fairway) Site Number : 8400008",
                    "status": "RECRUITING",
                    "city": "Fairway",
                    "state": "Kansas",
                    "zip": "66205-2528",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lisa Bogart",
                            "role": "CONTACT",
                            "phone": "913-945-7552",
                            "email": "CTNurseNav@kumc.edu"
                        },
                        {
                            "name": "Joaquina Baranda",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.02223,
                        "lon": -94.6319
                    }
                },
                {
                    "facility": "John Theurer Cancer Center Site Number : 8400001",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Suzanne Kosky",
                            "role": "CONTACT",
                            "phone": "551-996-3986",
                            "email": "suzanne.kosky@hmhn.org"
                        },
                        {
                            "name": "Martin Gutierrez",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Rhode Island Hospital Site Number : 8400004",
                    "status": "RECRUITING",
                    "city": "Providence",
                    "state": "Rhode Island",
                    "zip": "02903",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kaitlyn Krar",
                            "role": "CONTACT",
                            "phone": "401-444-4818",
                            "email": "CKrar@Lifespan.org"
                        },
                        {
                            "name": "Khaldoun Almhanna",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.82399,
                        "lon": -71.41283
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center Site Number : 8400005",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030-4000",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yali Yang",
                            "role": "CONTACT",
                            "phone": "713-794-5555",
                            "email": "anaing@mdanderson.org"
                        },
                        {
                            "name": "Aung Naing",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Hadassah Medical Center - PPDS_Investigational Site Number : 3760005",
                    "status": "RECRUITING",
                    "city": "Jerusalem",
                    "zip": "91120",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Jonathan Cohen",
                            "role": "CONTACT",
                            "phone": "972505172537",
                            "email": "cohenjon@hadassah.org.il"
                        },
                        {
                            "name": "Jonathan Cohen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.76904,
                        "lon": 35.21633
                    }
                },
                {
                    "facility": "Sheba Medical Center - PPDS_Investigational Site Number : 3760003",
                    "status": "RECRUITING",
                    "city": "Ramat Gan",
                    "zip": "5262100",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Tamar Beller",
                            "role": "CONTACT",
                            "phone": "972545964434",
                            "email": "Tamar.Beller@sheba.health.gov.il"
                        },
                        {
                            "name": "Tamar Beller",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08227,
                        "lon": 34.81065
                    }
                },
                {
                    "facility": "Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis_Investigational Site Number : 5280001",
                    "status": "RECRUITING",
                    "city": "Amsterdam",
                    "state": "Noord-Holland",
                    "zip": "1066 CX",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "name": "Marloes van Dongen",
                            "role": "CONTACT",
                            "phone": "31205129111",
                            "email": "mg.v.dongen@nki.nl"
                        },
                        {
                            "name": "Marloes van Dongen",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.37403,
                        "lon": 4.88969
                    }
                },
                {
                    "facility": "Erasmus MC_Investigational Site Number : 5280003",
                    "status": "RECRUITING",
                    "city": "Rotterdam",
                    "zip": "3015 GD",
                    "country": "Netherlands",
                    "contacts": [
                        {
                            "name": "Ferry Eskens",
                            "role": "CONTACT",
                            "phone": "31107034897",
                            "email": "f.eskens@erasmusmc.nl"
                        },
                        {
                            "name": "Ferry Eskens",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.9225,
                        "lon": 4.47917
                    }
                },
                {
                    "facility": "Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON_Investigational Site Number : 7240007",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Elena Garralda",
                            "role": "CONTACT",
                            "phone": "34932746085",
                            "email": "egarralda@vhio.net"
                        },
                        {
                            "name": "Elena Garralda",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "START MADRID_Hospital Universitario HM Sanchinarro - CIOCC_Investigational Site Number : 7240005",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28050",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Emiliano Calvo",
                            "role": "CONTACT",
                            "phone": "34917567825",
                            "email": "emiliano.calvo@startmadrid.com"
                        },
                        {
                            "name": "Emiliano Calvo",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068818",
                    "term": "Cetuximab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M315",
                    "name": "Cetuximab",
                    "asFound": "Physician",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}